7,8-Dihydroxyflavone suppresses proliferation and induces apoptosis of human osteosarcoma cells

Jing Zhao1, Peifeng Li2, Hua Zhu1

  • 1Department of Pharmacy, Clinical Medical College, Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou 225001, China.

Insights

7,8-dihydroxyflavone (7,8-DHF) inhibits osteosarcoma (OS) progression by reducing cell viability, promoting apoptosis, and inhibiting migration. This natural compound may offer a new therapeutic strategy for OS patients by modulating Akt/Bad and MAPK signaling pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Osteosarcoma (OS) is a primary bone malignancy with limited treatment options.
  • 7,8-dihydroxyflavone (7,8-DHF), a natural flavonoid, has shown anti-tumor properties in various cancers.
  • The role of 7,8-DHF in OS development and its underlying mechanisms are currently unknown.

Purpose of the Study:

  • To investigate the anti-cancer effects of 7,8-DHF on human osteosarcoma cell lines.
  • To elucidate the molecular mechanisms by which 7,8-DHF influences OS progression.
  • To evaluate the potential of 7,8-DHF as a therapeutic agent for osteosarcoma.

Main Methods:

  • Human OS cell lines (U2OS, 143B) were treated with 7,8-DHF.
  • Cell viability assessed via MTT assay; migration via wound-healing assay.
  • Apoptosis, reactive oxygen species (ROS), and signaling pathway proteins (Akt, Bad, MAPK, ERK, JNK) analyzed using TUNEL, fluorescent probes, and Western blot.

Main Results:

  • 7,8-DHF significantly reduced OS cell viability and migration in a dose-dependent manner.
  • Treatment with 7,8-DHF induced oxidative stress and promoted apoptosis in OS cells.
  • 7,8-DHF modulated key signaling pathways, inhibiting Akt/Bad and p38MAPK while activating ERK/JNK.

Conclusions:

  • 7,8-dihydroxyflavone demonstrates significant anti-osteosarcoma activity.
  • The anti-tumor effects of 7,8-DHF in OS are mediated through the regulation of Akt/Bad and MAPK signaling pathways.
  • 7,8-DHF presents a promising candidate for novel therapeutic strategies in osteosarcoma treatment.